Article Menu
Need Help?
No Article Versions Notes Found
Cite
Masucci, L.; Torres, S.; Eisen, A.; Trudeau, M.; Tyono, I.; Saunders, H.; Chan, K.W.; Isaranuwatchai, W. Cost–Utility Analysis of 21-Gene Assay for Node-Positive Early Breast Cancer. Curr. Oncol. 2019, 26, 307-318. https://doi.org/10.3747/co.26.4769
Masucci L, Torres S, Eisen A, Trudeau M, Tyono I, Saunders H, Chan KW, Isaranuwatchai W. Cost–Utility Analysis of 21-Gene Assay for Node-Positive Early Breast Cancer. Current Oncology. 2019; 26(5):307-318. https://doi.org/10.3747/co.26.4769
Chicago/Turabian StyleMasucci, L., S. Torres, A. Eisen, M. Trudeau, I. Tyono, H. Saunders, K.W. Chan, and W. Isaranuwatchai. 2019. "Cost–Utility Analysis of 21-Gene Assay for Node-Positive Early Breast Cancer" Current Oncology 26, no. 5: 307-318. https://doi.org/10.3747/co.26.4769
APA StyleMasucci, L., Torres, S., Eisen, A., Trudeau, M., Tyono, I., Saunders, H., Chan, K. W., & Isaranuwatchai, W. (2019). Cost–Utility Analysis of 21-Gene Assay for Node-Positive Early Breast Cancer. Current Oncology, 26(5), 307-318. https://doi.org/10.3747/co.26.4769
